Stryker's Q3 Miss Expected, But Negative Tone on Underperformance Unexpected, Truist Says

MT Newswires Live10-31 02:57

Stryker's (SYK) Q3 miss and lower guidance were anticipated, but its comments about underperformance in the hip and knee end markets were more negative than expected, Truist Securities said in a Friday note.

The company reported Q3 adjusted earnings late Thursday of $3.52 per diluted share on revenue of $6.52 billion. Analysts polled by FactSet expected EPS of $3.55 on revenue of $6.62 billion.

Stryker attributed the underperformance in the end market for hip- and knee-replacement procedures to factors such as a softer market, increased hurdles for patients' surgery approvals, product gaps, and slower-than-expected adoption of new products, according to the note.

The firm had expected a clear idea for 2027, with organic revenue growth toward 6% to 7%, which is below Truist estimates and consensus, but Stryker is likely setting a de-risked guidance for its new incoming CEO Spencer Stiles, according to the note.

Truist reiterated the company's stock rating at hold and lowered the price target to $305 from $310.

Price: 295.42, Change: -16.33, Percent Change: -5.24

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment